Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

Vaccine

Volumn 25, Issue 20, 2007, Pages 4038-4045

  Halloran, M Elizabeth ^a,b   Piedra, Pedro A ^d   Longini Jr , Ira M ^a,b   Gaglani, Manjusha J ^c   Schmotzer, Brian ^e   Fewlass, Charles ^c   Herschler, Gayla B ^c   Glezen, W Paul ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Efficacy; Influenza; Surveillance; Vaccine

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; TRIPLE VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; COLD ACCLIMATIZATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNITY; INFLUENZA; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; VACCINATION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, HERD; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; TEXAS;

EID: 34247365482     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.060     Document Type: Article

References (15)

1. Gaglani M.J., Piedra P.A., Herschler G.B., Griffith M.E., Kozinetz C.A., Riggs M.W.,., et al. Direct effectiveness of the trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against the 2000-2001 influenza A (H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158 (2004) 65-73
2. Piedra P.A., Gaglani M.J., Kozinetz C.A., Herschler G., Riggs M., Griffith M.,., et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23 (2005) 1540-1548
3. Piedra P.A., Gaglani M.J., Riggs M., Herschler G., Fewlass C., Watts M.,., et al. Live attenuated influenza vaccine, trivalen, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116 (2005) 397-407
4. Longini I.M., Halloran M.E., Nizam A., Wolff M., Mendelman P.M., Fast P.,., et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 18 (2000) 1902-1909
5. Halloran M.E., Longini I.M., Gaglani M.J., Piedra P.A., Chu H., Herschler G.B.,., et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 158 (2003) 305-311
6. Halloran M.E., and Longini I.M. Using validation sets for outcomes and exposure to infection in vaccine field studies. Am J Epidemiol 154 (2001) 391-398
7. Scharfstein D.O., Halloran M.E., Chu H., and Daniels M.J. On estimation of vaccine efficacy using validation samples with selection bias. Biostatistics 7 (2006) 615-629 [Biostatistics Advanced Access published on March 23, 2006]
8. PA Piedra, MJ Gaglani, CA Kozinetz, GB Herschler, C Fewlass, D Harvey, et al. Live attenuated intranasal influenza vaccine-trivalent (LAIV-T) administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct and indirect protection in children. Pediatrics, in press.
9. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B.,., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy working adults: a randomized controlled trial. J Am Med Assoc 282 (1999) 137-144
10. Efron B., and Tibshirani R.J. An introduction to the bootstrap (1993), Chapman and Hall, New York
11. CDC. Assessment of the effectiveness of the 2003-2004 influenza vaccine among children and adults-Colorado, 2003. MMWR 2004;53:707-10.
12. Longini I.M., Nizam A., Xu S., Ungchusak K., and Hanshaoworakul W. DAT Cummings, and ME Halloran. Science 309 (2005) 1083-1087
13. Germann T.C., Kadau K., Longini I.M., and Macken C.A. Mitigation strategies for pandemic influenza in the United States. PNAS 103 (2006) 5935-5940
14. Ferguson N.M., Cummings D.A.T., Fraser C., Cajka J.C., Cooley P.C., and Burke D.S. Strategies for mitigating an influenza pandemic. Nature 442 (2006) 252-448 10.1038/nature04795
15. Little R.J.A., and Rubin D.A. Statistical analysis with missing data. 2nd ed. (2002), John Wiley, Hoboken, New Jersey